Ultragenyx Pharmaceutical Inc.
RARE
$39.11
-$0.53-1.34%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.28% | 16.37% | 17.66% | -4.09% | 18.86% |
| Total Depreciation and Amortization | 10.48% | 21.78% | 65.30% | 68.93% | 65.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.14% | -15.25% | -5.56% | -32.57% | -48.79% |
| Change in Net Operating Assets | 71.01% | 1,001.00% | 128.50% | -46.02% | -39.11% |
| Cash from Operations | 5.25% | 43.16% | 33.74% | -21.59% | 7.13% |
| Capital Expenditure | 59.13% | 56.24% | 85.59% | 87.17% | 94.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 198.08% | -502.83% | -44.80% | -28.38% | 27.30% |
| Cash from Investing | 196.00% | -528.50% | -39.08% | -15.16% | 37.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.04% | -83.46% | 1,090.62% | -- | 16,422.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -91.64% | 91.97% | 100.00% |
| Cash from Financing | -99.04% | -55.72% | 1,065.78% | 91.97% | 17,466.95% |
| Foreign Exchange rate Adjustments | -324.21% | 278.07% | -376.47% | -421.80% | -18.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -82.99% | -1,035.71% | 2,179.24% | -110.59% | 154.42% |
